MAU868
BK Virus Viremia in Kidney Transplant Patients
Phase 2Completed; showed clinically meaningful reductions
Key Facts
Indication
BK Virus Viremia in Kidney Transplant Patients
Phase
Phase 2
Status
Completed; showed clinically meaningful reductions
Company
About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotech focused on developing transformative treatments for B-cell and plasma cell-driven autoimmune diseases. Its core achievement is the successful Phase 3 ORIGIN 3 trial of atacicept in IgA nephropathy (IgAN), meeting its primary endpoint in June 2025, which sets the stage for a potential first-in-class therapy. The company's strategy leverages a deep understanding of B-cell biology to selectively target pathogenic drivers, with a lean operational model aimed at efficiently advancing its pipeline toward commercialization and addressing high unmet medical needs.
View full company profile